Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
4,584 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02715362 | A Study of GPC3 Redirected Autologous T Cells for Advanced HCC(GPC3-CART) | unknown | Phase 1 / Phase 2 | 30 | Shanghai GeneChem Co., Ltd.INDUSTRY | 1 | Mar 22, 2016 | clinicaltrials |
| NCT02706782 | A Study of Mesothelin Redirected Autologous T Cells for Advanced Pancreatic Carcinoma(meso-CART) | unknown | Phase 1 | 30 | Shanghai GeneChem Co., Ltd.INDUSTRY | 1 | Mar 11, 2016 |
| clinicaltrials |
| NCT01637805 | Clinical Safety and Preliminary Efficacy of AAV-DC-CTL Treatment in Stage IV Gastric Cancer(AAV-DC-CTL) | unknown | Phase 1 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Mar 8, 2016 | clinicaltrials |
| NCT02693236 | DC Vaccine Combined With CIK Cells in Patients With Esophagus Cancer | unknown | Phase 1 / Phase 2 | 30 | Affiliated Hospital to Academy of Military Medical SciencesOTHER | 1 | Feb 26, 2016 | clinicaltrials |
| NCT01690507 | Decitabine Combining Modified CAG Followed by HLA Haploidentical Peripheral Blood Mononuclear Cells Infusion for Elderly Patients With Acute Myeloid Leukemia(AML） | completed | Phase 1 / Phase 2 | 29 | Chinese PLA General HospitalOTHER | 1 | Feb 25, 2016 | clinicaltrials |
| NCT02447263 | HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Liver Cancer | completed | Phase 1 / Phase 2 | 87 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Feb 25, 2016 | clinicaltrials |
| NCT02449109 | Nano Drug Interventional Therapy Using Digital Subtraction Angiography（DSA） for Liver Carcinoma | completed | Phase 1 / Phase 2 | 60 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Feb 25, 2016 | clinicaltrials |
| NCT02449122 | Nano Drug Interventional Therapy Using Digital Subtraction Angiography（DSA） for Lung Carcinoma | completed | Phase 1 / Phase 2 | 60 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Feb 25, 2016 | clinicaltrials |
| NCT02523417 | HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA）for Breast Cancer | completed | Phase 1 / Phase 2 | 15 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Feb 25, 2016 | clinicaltrials |
| NCT02156388 | Safety and Pharmacokinetic(PK) Study of GW003 to Metastatic Tumors | completed | Phase 1 | 31 | Jiangsu T-Mab Biopharma Co.,LtdINDUSTRY | 1 | Feb 24, 2016 | clinicaltrials |
| NCT02688686 | Safety and Efficacy of DC-CIK in Patients With Advanced Non-Small-Cell Lung Cancer With Bone Metastases | unknown | Phase 1 / Phase 2 | 30 | Affiliated Hospital to Academy of Military Medical SciencesOTHER | 1 | Feb 23, 2016 | clinicaltrials |
| NCT01924156 | DC Vaccine Combined With CIK Cells in Patients With Renal Cell Carcinoma | unknown | Phase 1 / Phase 2 | 30 | Affiliated Hospital to Academy of Military Medical SciencesOTHER | 1 | Feb 22, 2016 | clinicaltrials |
| NCT01956630 | Clinical Study of DC Plus CIK for Patients With Relapse Acute Leukemia After Allo-HSCT | unknown | Phase 1 / Phase 2 | 25 | Affiliated Hospital to Academy of Military Medical SciencesOTHER | 1 | Feb 22, 2016 | clinicaltrials |
| NCT02672501 | A Study to Assess CD19-targeted Immunotherapy T Cells in Patients With Relapsed or Refractory CD19+ B Cell Leukemia | unknown | Phase 1 / Phase 2 | 30 | Shanghai GeneChem Co., Ltd.INDUSTRY | 1 | Feb 3, 2016 | clinicaltrials |
| NCT01799083 | Lower Dose Decitabine Based Therapy in Patients With Refractory and/or Chemotherapy Resistant Solid Tumors or B Cell Lymphomas(CIK) | unknown | Phase 1 / Phase 2 | 100 | Han weidongOTHER | 1 | Jan 28, 2016 | clinicaltrials |
| NCT01864902 | Treatment of Relapsed and/or Chemotherapy Refractory CD33 Positive Acute Myeloid Leukemia by CART-33(CART33) | unknown | Phase 1 / Phase 2 | 10 | Chinese PLA General HospitalOTHER | 1 | Jan 28, 2016 | clinicaltrials |
| NCT01886976 | Treatment of Chemotherapy Refractory Multiple Myeloma by CART-138(CART-138) | unknown | Phase 1 / Phase 2 | 10 | Chinese PLA General HospitalOTHER | 1 | Jan 28, 2016 | clinicaltrials |
| NCT01935843 | Treatment of Chemotherapy Refractory Human Epidermalgrowth Factor Receptor-2( HER-2) Positive Advanced Solid Tumors(CART-HER-2) | unknown | Phase 1 / Phase 2 | 10 | Chinese PLA General HospitalOTHER | 1 | Jan 28, 2016 | clinicaltrials |
| NCT02259556 | CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas(CART30) | recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Jan 28, 2016 | clinicaltrials |
| NCT02662348 | T Cell Mediated Adaptive Therapy for Her2-positive Neoplasms of Digestive System | unknown | Phase 1 | 6 | Yi MiaoOTHER | 1 | Jan 25, 2016 | clinicaltrials |
| NCT02403544 | Phase I Study of Image-Guided Radiation Concurrent With Double-Agent Chemotherapy for Hepatocellular Carcinoma | unknown | Phase 1 | 30 | Chinese Academy of Medical SciencesOTHER | 1 | Jan 5, 2016 | clinicaltrials |
| NCT02489916 | Donafenib Monotherapy for Previously Treated Metastatic Colorectal Cancer | completed | Phase 1 / Phase 2 | 47 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Jan 5, 2016 | clinicaltrials |
| NCT02632006 | Immunotherapy Using Pluripotent Killer-Programmed Cell Death 1 (PIK-PD-1) Cells for the Treatment of Advanced Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 40 | Second Military Medical UniversityOTHER | 1 | Jan 1, 2016 | clinicaltrials |
| NCT02632019 | Immunotherapy Using Precision T Cells Specific to Personalized Neo-antigen for the Treatment of Advanced Malignant Tumor of Biliary Tract | unknown | Phase 1 / Phase 2 | 40 | Second Military Medical UniversityOTHER | 1 | Jan 1, 2016 | clinicaltrials |
| NCT02632188 | Radical Surgery Followed by Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen for the Treatment of Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 60 | Second Military Medical UniversityOTHER | 1 | Jan 1, 2016 | clinicaltrials |
| NCT02632201 | Immunotherapy Using Pluripotent Killer-Human Epidermal Growth Factor Receptor-2 (PIK-HER2) Cells for the Treatment of Advanced Gastric Cancer With Liver Metastasis | unknown | Phase 1 / Phase 2 | 40 | Second Military Medical UniversityOTHER | 1 | Jan 1, 2016 | clinicaltrials |
| NCT02638857 | Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen Combined With Transcatheter Arterial Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 60 | Second Military Medical UniversityOTHER | 1 | Jan 1, 2016 | clinicaltrials |
| NCT02644655 | Immunotherapy Using Autologous T Cell-Engineered With CD19-specific Chimeric Antigen Receptor for the Treatment of Recurrent /Refractory B Cell Leukemia | unknown | Phase 1 / Phase 2 | 20 | Second Military Medical UniversityOTHER | 1 | Jan 1, 2016 | clinicaltrials |
| NCT02004548 | Phase I Clinical Study of Metatinib Tromethamine Tablet | completed | Phase 1 | 18 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 29, 2015 | clinicaltrials |
| NCT01694472 | Clinical Safety and Preliminary Efficacy of MAGE-A4 TCR Gene-Modified T Cells to Treat Malignant Tumors | unknown | Phase 1 | 15 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 22, 2015 | clinicaltrials |
| NCT02133079 | Immunotherapy of Tumor With Autologous Tumor Derived Heat Shock Protein gp96 | unknown | Phase 1 / Phase 2 | 20 | Cure&Sure Biotech Co., LTDINDUSTRY | 1 | Dec 11, 2015 | clinicaltrials |
| NCT02619058 | A Clinical Trial of Adoptive Transfer With Autologous NKT Cells in Metastatic Melanoma Patients | unknown | Phase 1 | 20 | Peking University Cancer Hospital & InstituteOTHER | 1 | Dec 4, 2015 | clinicaltrials |
| NCT01833923 | A Phase I Study of Anlotinib on Tolerance and Pharmacokinetics(ALTN) | completed | Phase 1 | 35 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Oct 28, 2015 | clinicaltrials |
| NCT02580747 | Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso | unknown | Phase 1 | 20 | Chinese PLA General HospitalOTHER | 1 | Oct 20, 2015 | clinicaltrials |
| NCT01735604 | Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy | unknown | Phase 1 / Phase 2 | 50 | Chinese PLA General HospitalOTHER | 1 | Sep 29, 2015 | clinicaltrials |
| NCT01869166 | Treatment of Chemotherapy Refractory EGFR(Epidermal Growth Factor Receptor) Positive Advanced Solid Tumors (CART-EGFR)(CART-EGFR) | unknown | Phase 1 / Phase 2 | 60 | Chinese PLA General HospitalOTHER | 1 | Sep 29, 2015 | clinicaltrials |
| NCT02333474 | Safety and Efficacy of Mix Vaccine in Lung Carcinoma Patient | completed | Phase 1 / Phase 2 | 20 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 10, 2015 | clinicaltrials |
| NCT02338700 | Safety and Efficacy Study of Mix Vaccine in Prostate Carcinoma Patient | completed | Phase 1 / Phase 2 | 20 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 10, 2015 | clinicaltrials |
| NCT02338778 | Safety and Efficacy Study of Mix Vaccine in Hepatocyte Carcinoma Patient | completed | Phase 1 / Phase 2 | 20 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 10, 2015 | clinicaltrials |
| NCT02338804 | Safety and Efficacy Study of Mix Vaccine in Breast Carcinoma Patient | completed | Phase 1 / Phase 2 | 20 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 10, 2015 | clinicaltrials |
| NCT02529579 | Safety and Efficacy Evaluation of iAPA-DC/CTL Combined Gemcitabine Therapy on Advanced Pancreatic Cancer | unknown | Phase 1 / Phase 2 | 187 | Changhai HospitalOTHER | 1 | Aug 20, 2015 | clinicaltrials |
| NCT00950417 | Nimotuzumab in Combination With Chemoradiation for Esophageal Cancer | completed | Phase 1 | 11 | Biotech Pharmaceutical Co., Ltd.OTHER | 1 | Aug 19, 2015 | clinicaltrials |
| NCT00985998 | Nimotuzumab in Combination With Cisplatin and Docetaxel for Patients With Advanced Non-small Cell Lung Cancer | withdrawn | Phase 1 | 0 | Biotech Pharmaceutical Co., Ltd.OTHER | 1 | Aug 19, 2015 | clinicaltrials |
| NCT02395068 | Pharmacokinetics Study of Nimotuzumab in Patients With Solid Tumors | unknown | Phase 1 | 40 | Biotech Pharmaceutical Co., Ltd.OTHER | 1 | Aug 19, 2015 | clinicaltrials |
| NCT01812096 | Study of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma in China(MM) | unknown | Phase 1 / Phase 2 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Aug 18, 2015 | clinicaltrials |
| NCT01482936 | Pharmacokinetic (PK) Study of OxyNorm Injections in Chinese Patient | completed | Phase 1 | 44 | Mundipharma (China) Pharmaceutical Co. LtdINDUSTRY | 1 | Aug 11, 2015 | clinicaltrials |
| NCT02233205 | Safety Study of Combining Ultrasound Microbubbles and Chemotherapy to Treat Malignant Neoplasms of Digestive System | unknown | Phase 1 / Phase 2 | 18 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jul 24, 2015 | clinicaltrials |
| NCT02024633 | Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer | unknown | Phase 1 | 24 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jul 15, 2015 | clinicaltrials |
| NCT02496949 | A Phase Ib Study to Assess Safety and Efficacy of Oral Icaritin in Advanced Solid Tumors | completed | Phase 1 | 28 | Chinese Academy of Medical SciencesOTHER | 1 | Jul 14, 2015 | clinicaltrials |
| NCT02469883 | A Study of Sinotecean on Tolerance and Pharmacokinetics | unknown | Phase 1 | 20 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jun 12, 2015 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials